Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma
- Determine the response rate, duration of response, and overall survival of patients
with refractory or relapsed ovarian epithelial cancer treated with high-dose
cyclophosphamide, carboplatin, and mitoxantrone followed by autologous bone marrow
- Determine the nonhematopoietic toxicity of this regimen in these patients.
OUTLINE: Autologous bone marrow is harvested before study entry. Patients receive high-dose
cyclophosphamide IV over 1 hour and mitoxantrone IV over 15 minutes on days -8, -6, and -4
and carboplatin IV continuously on days -8 to -3 in the absence of unacceptable toxicity.
Bone marrow is reinfused on day 0 beginning at least 60 hours after completion of
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 1.5-3
Masking: Open Label, Primary Purpose: Treatment
Patrick J. Stiff, MD
United States: Federal Government
|Cardinal Bernardin Cancer Center at Loyola University Medical Center||Maywood, Illinois 60153-5500|